Intellia filing spurs safety concerns over CRISPR drug

Intellia filing spurs safety concerns over CRISPR drug

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study participant given one of its gene editing treatments.

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity

Intellia Therapeutics (NASDAQ: NTLA) found out this past week what other genetic medicine developers have learned in recent weeks: Any safety issue that arises in a clinical trial is enough to send investors scrambling to sell their shares. Intellia saw its stock tumble 23% Thursday to $7.45 from $9.66 at Wednesday’s closing bell. In between, Intellia filed a Form 8-K on Wednesday evening revealing that one of about 365 patients enrolled in the …

Intellia stock dips following safety event in Phase III gene therapy trial

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been reported.The post Intellia stock dips following safety event in Phase III gene therapy trial appeared first on Clinical Trials Arena.